Literature DB >> 20503107

MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis.

Fang Fang1, Xiao-Jia Yu, Lu Yu, Lei Yao.   

Abstract

The murine double minute 2 (MDM2) gene encodes an important regulator which mainly functions as an E3 ligase. The role of the MDM2 protein in the P53 pathway has been especially well-studied. In this study, our aim was to explore the relationship between MDM2 gene 309 T/G polymorphism and colorectal cancer risk. Performing both the overall meta-analysis and the subgroup meta-analysis based on ethnicity and source of controls with a total of 7 eligible studies (2,543 cases and 2,115 controls in all), we detected a significant colorectal cancer risk variation for TG versus GG (OR=0.73, 95% CI=0.62-0.86) in the overall analysis and another significant colorectal cancer risk variation for TG versus GG (OR=0.70, 95% CI=0.59-0.83) in the population-based controls' subgroup as well. Moreover, in the subgroup analysis based on ethnicity, significant associations were observed for all genetic models in Asians (OR=0.51, 95% CI=0.41-0.64 for TT versus GG; OR=0.64, 95% CI=0.53-0.78 for TG versus GG; OR=0.59, 95% CI=0.49-0.71 for dominant model; OR=0.69, 95% CI=0.57-0.82 for recessive model), while in Caucasians there was no obvious association. In summary, according to the results of our meta-analysis, the MDM2 309 G allele probably acts as a colorectal cancer risk factor, especially in Asians.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503107     DOI: 10.1007/s12032-010-9577-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

Review 1.  The p53-Mdm2 module and the ubiquitin system.

Authors:  Dan Michael; Moshe Oren
Journal:  Semin Cancer Biol       Date:  2003-02       Impact factor: 15.707

2.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

3.  MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.

Authors:  Bente A Talseth; Cliff Meldrum; Janina Suchy; Grzegroz Kurzawski; Jan Lubinski; Rodney J Scott
Journal:  Int J Cancer       Date:  2007-02-01       Impact factor: 7.396

4.  Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.

Authors:  Konstantinos P Economopoulos; Theodoros N Sergentanis
Journal:  Breast Cancer Res Treat       Date:  2009-07-10       Impact factor: 4.872

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells.

Authors:  Hafid Alazzouzi; Gianpaolo Suriano; Angel Guerra; Alberto Plaja; Eloi Espín; Manel Armengol; Pia Alhopuro; Sergia Velho; Yasuhisa Shinomura; Juan José González-Aguilera; Hiroyuki Yamamoto; Lauri A Aaltonen; Víctor Moreno; Gabriel Capellà; Miguel Angel Peinado; Raquel Seruca; Diego Arango; Simó Schwartz
Journal:  J Med Genet       Date:  2006-07-06       Impact factor: 6.318

Review 7.  Molecular origins of cancer: Molecular basis of colorectal cancer.

Authors:  Sanford D Markowitz; Monica M Bertagnolli
Journal:  N Engl J Med       Date:  2009-12-17       Impact factor: 91.245

8.  Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.

Authors:  Osamu Nunobiki; Masatsugu Ueda; Michiko Yamamoto; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-11       Impact factor: 4.174

9.  Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer.

Authors:  Masatsugu Ueda; Michiko Yamamoto; Osamu Nunobiki; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-05       Impact factor: 4.174

10.  Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women.

Authors:  Shan Kang; Dong-Jie Wang; Wan-Sheng Li; Na Wang; Rong-Miao Zhou; Dong-Lan Sun; Ya-Nan Duan; Shi-Zhen Li; Xiao-Fei Li; Yan Li
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

View more
  4 in total

1.  Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Yu-jing Huang; Zhensheng Liu; Li-E Wang; Guojun Li; Erich M Sturgis; David G Johnson; Qingyi Wei
Journal:  Mol Carcinog       Date:  2011-06-07       Impact factor: 4.784

2.  TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.

Authors:  Rym Abderrahmane; Lotfi Louhibi; Fatima Zohra Moghtit; Amina Boubekeur; Khedidja Benseddik; Abdellah Boudjema; Fouzia Benrrahal; Meriem Aberkane; Mostefa Fodil; Nadhira Saidi-Mehtar
Journal:  Pathol Oncol Res       Date:  2014-12-24       Impact factor: 3.201

3.  Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Li-E Wang; Zhensheng Liu; Sheng Wei; Guojun Li; Erich M Sturgis; Qingyi Wei
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

4.  An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk.

Authors:  Xue Qin; Qiliu Peng; Weizhong Tang; Xianjun Lao; Zhiping Chen; Hao Lai; Yan Deng; Cuiju Mo; Jingzhe Sui; Junrong Wu; Limin Zhai; Shi Yang; Shan Li; Jinmin Zhao
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.